STOCK TITAN

Eloxx Pharmaceuticals, Inc. - $ELOX STOCK NEWS

Welcome to our dedicated page for Eloxx Pharmaceuticals news (Ticker: $ELOX), a resource for investors and traders seeking the latest updates and insights on Eloxx Pharmaceuticals stock.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) is a clinical-stage biopharmaceutical company focused on the development of novel RNA-modulating drug candidates designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are genetic mutations that disrupt protein synthesis, leading to severe genetic disorders. With over 1,800 identified rare diseases caused by these mutations, Eloxx is at the forefront of innovative genetic therapies.

The company's lead product candidate, ELX-02, is a small molecule drug designed to restore production of full-length functional proteins. Currently in Phase 2 clinical development, ELX-02 has shown promise in treating Alport syndrome, a genetic disorder characterized by kidney disease, hearing loss, and eye abnormalities.

Recent advancements include confirmation of ELX-02's disease-modifying potential in Alport syndrome, with positive results from patient biopsies in clinical trials. Eloxx has also submitted an Investigational New Drug (IND) application to the U.S. FDA for ELX-02, aiming to include U.S.-based sites in its pivotal trials.

Additionally, Eloxx is developing ZKN-013, a TURBO-ZM™ based molecule for treating recessive dystrophic epidermolysis bullosa (RDEB) and other genetic conditions. The company has initiated strategic partnerships and aims to begin patient dosing by the end of 2023.

Financially, Eloxx reported a net loss of $3.6 million for Q3 2023 but has shown a decrease in overall R&D and administrative expenses compared to the previous year. The company is focused on improving its liquidity position and raising additional capital to fund operations through 2023 and beyond.

Eloxx continues to leverage its TURBO-ZM™ chemistry platform to develop novel Ribosome Modulating Agents (RMAs) and maintain its commitment to addressing the unmet medical needs of patients with rare genetic disorders. For the latest updates and detailed information, visit www.eloxxpharma.com.

Rhea-AI Summary
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX) has received an extension from the Nasdaq Listing Qualifications Panel to regain compliance with the minimum market value of listed securities requirement. The extension, until October 9, 2023, will allow the company to execute its plan to meet Nasdaq's standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.32%
Tags
none
-
Rhea-AI Summary
Eloxx Pharmaceuticals has announced the publication of a study demonstrating the potential of its TURBO-ZM chemistry technology platform to develop novel Ribosome Modulating Agents (RMAs) for the treatment of colorectal cancer. The study shows that the novel RMA, ZKN-157, has demonstrated activity against subtypes of colorectal cancer, particularly the CMS2 subtype characterized by high MYC activity. This research opens up opportunities to selectively target MYC-driven cancers with a novel mechanism and potentially synergize with existing cancer therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.01%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.69%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.69%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.28%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.67%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.63%
Tags
none

FAQ

What is Eloxx Pharmaceuticals' primary focus?

Eloxx Pharmaceuticals focuses on developing RNA-modulating drug candidates to treat rare and ultra-rare premature stop codon diseases.

What is ELX-02?

ELX-02 is Eloxx's lead product candidate, a small molecule drug designed to restore production of full-length functional proteins, currently in Phase 2 clinical development for treating Alport syndrome.

What is the significance of premature stop codons?

Premature stop codons are genetic mutations that disrupt protein synthesis, leading to severe genetic disorders. Eloxx targets these mutations to restore protein production.

What are the recent advancements with ELX-02?

ELX-02 has shown disease-modifying potential in clinical trials for Alport syndrome, with positive results in patient biopsies and an IND submission to the FDA for further trials.

What is ZKN-013?

ZKN-013 is a TURBO-ZM™ based molecule under development by Eloxx for treating recessive dystrophic epidermolysis bullosa (RDEB) and other genetic conditions.

How is Eloxx Pharmaceuticals performing financially?

Eloxx reported a net loss of $3.6 million for Q3 2023, with decreased R&D and administrative expenses compared to the previous year. The company is focused on improving liquidity and raising additional capital.

What is the TURBO-ZM™ platform?

The TURBO-ZM™ platform is Eloxx's innovative chemistry technology platform used to develop novel Ribosome Modulating Agents (RMAs) for treating genetic disorders.

What are the challenges Eloxx Pharmaceuticals is facing?

Eloxx is focused on improving its liquidity position, raising additional capital, and maintaining compliance with Nasdaq listing requirements.

What are Eloxx's future plans?

Eloxx plans to advance ELX-02 into pivotal trials for Alport syndrome, initiate clinical studies for ZKN-013, and continue leveraging their TURBO-ZM™ platform for new therapies.

Where can I find more information about Eloxx Pharmaceuticals?

For more information, visit Eloxx Pharmaceuticals' official website at www.eloxxpharma.com.

Eloxx Pharmaceuticals, Inc.

Nasdaq:ELOX

ELOX Rankings

ELOX Stock Data

2.20M
2.78M
0.41%
15.61%
0.7%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
Waltham